CytoMed Therapeutics (GDTC) announces that the first patient has been dosed in its first-in-human Phase I dose-escalation clinical trial, ANGELICA trial. This trial has been registered with and has received clinical trial authorization from the Health Sciences Authority in Singapore. The ANGELICA Trial evaluates allogeneic NKG2DL-targeting chimeric antigen receptor-grafted gamma delta T cells in patients with advanced solid tumours or haematological malignancies. Refer to Form 6K announcement on October 7, 2024. “Dosing the first patient in the ANGELICA Trial, CytoMed has reached a significant milestone as a clinical stage biopharma,” says Chairman Peter Choo. “The ANGELICA Trial aims to assess the safety and potential efficacy of an allogeneic CAR-T therapy patients with advanced solid tumours or haematological malignancies.”
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDTC:
- CytoMed Launches Innovative CAR-T Cell Trial
- Cytomed Therapeutics announces NMRC co-funding support for ANGELICA trial
- Cytomed Therapeutics acquires assets and license of Malaysian cord blood bank
- CytoMed Acquires Cord Blood Assets, Eyes Regenerative Medicine
- Cytomed Therapeutics 1H EPS (S$0.09) vs. (S$0.22) last year